Silvia Giannini, Ph.D. Email & Phone Number

Boston, MA, US

Work focused on the development of iPSC-derived platelet like cells for treating bleeding, autoimmune and malignant disorders.Lead the in vivo pharmacology team supporting the advancement of projects from early discovery to clinical evaluation. Design and execute PK, PD, biodistribution and efficacy studies to test lead drug candidates.Develop mouse models.

Cambridge, MA

Brigham And Women's Hospital/Harvard Medical School, Boston

Group leader managing a laboratory focused on evaluating the potential application of glycanmodifications as an avenue to regulate hematopoiesis in hematologicconditions.Relevant publications: 1. Giannini S, Lee-Sundlov M, Rivadeneyra L, Di Buduo CA, Burns R, Lau JT, Falet H, Balduini A, Hoffmeister KM. β4GALT1 controls β1 integrin function to govern.

Brigham And Women's Hospital/Harvard Medical School

• Research focused in understanding glycan-mediated mechanisms controlling blood cell production by regulating cell adhesion and migration with the purpose to develop new strategies to treat patients with inpaired.
• R01 HL 134829, National Institutes of Health (NIH) - The role of Glycans in thrombopoiesis 2017-2021
• Bridge Grant Award. American Society of Hematology (ASH). 2017-2018
• Fund to Sustain Research. Brigham and Women's Hospital Biomedical Research Institute. 2016-2017
• Chair’s Research Award. Research Performance Incentive Program. Brigham and Women’s Hospital, Boston. 2017Relevant publications: 1. Elf et al. Mutant Calreticulin Requires Both Its Mutant C-terminus and the.

Brigham And Women's Hospital/Harvard Medical School

Worked within Dr. Karin Hoffmeister and Dr. Hervé Falet’s laboratories which focus on understanding the mechanisms of platelet production and clearanceRelevant publications:1. Bender M*, Giannini S*, et al. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood. 2015. *Co-first authorship2. Jurak Begonja A, et al..

Perugia, Italy

• Work focused on studying the mechanisms of platelet activation and its contribution to ischemic cardiovascular disease.
• Studied the role of platelet-derived matrix metallo-proteinase 2 (MMP2) and CD40L in facilitating platelet and endothelial cell activation
• Demonstrated that viral infection but not antiretroviral therapy, is responsible for the endothelial cell dysfunction observed in patients with chronic HIV infection
• Proved that hyperglycemia-induced platelet activation is reversed by a nitric oxide-donating agent but not by aspirin in patients with type-2 diabetesRelevant publications:1. Falcinelli et al. Platelets release active.

Doctor Of Philosophy (Phd), Biology And Molecular Biotechnology

Worked within Dr. Paolo Gresele’s laboratory on the study of rare congenital and acquired hemostatic disorders • Developed flow cytometric.

Master Of Science (Ms), Biological Sciences

Thesis: Priming of platelet activation by human β-N-acetyl exosaminidase